Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ASRT

ASRT - Assertio Therapeutics Inc Stock Price, Fair Value and News

$11.84-0.42 (-3.43%)
Market Closed

14/100

ASRT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

14/100

ASRT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$9.21

Target 3M

$10.36

Target 6M

$9.78

ASRT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ASRT Price Action

Last 7 days

3.1%

Last 30 days

24.2%

Last 90 days

5.2%

Trailing 12 Months

-2.5%

ASRT RSI Chart

ASRT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ASRT Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-39.4

Price/Sales (Trailing)

8.3

EV/EBITDA

441.29

Price/Free Cashflow

85.47

ASRT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$9.21

Target 3M

$10.36

Target 6M

$9.78

ASRT Fundamentals

ASRT Revenue

Revenue (TTM)

137.4M

Rev. Growth (Yr)

69.36%

Rev. Growth (Qtr)

69.25%

ASRT Earnings

Earnings (TTM)

-28.9M

Earnings Growth (Yr)

491.82%

Earnings Growth (Qtr)

169.99%

ASRT Profitability

EBT Margin

-21.07%

Return on Equity

-27.34%

Return on Assets

-9.05%

Free Cashflow Yield

1.17%

ASRT Investor Care

Shares Dilution (1Y)

0.81%

Diluted EPS (TTM)

-0.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025119.0M117.1M137.4M0
2024142.1M132.2M125.8M125.0M
2023162.2M168.0M169.4M152.1M
2022120.7M130.5M139.2M156.2M
2021112.2M117.0M107.9M111.0M
2020198.7M167.9M137.1M106.3M
2019000229.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About Assertio Therapeutics Inc

ASRT
Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
 CEO
 WEBSITEassertiotx.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES30

Assertio Therapeutics Inc Frequently Asked Questions

ASRT is the stock ticker symbol of Assertio Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Assertio Therapeutics Inc is 1.14 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ASRT's fair value in chart for subscribers.

The fair value guage provides a quick view whether ASRT is over valued or under valued. Whether Assertio Therapeutics Inc is cheap or expensive depends on the assumptions which impact Assertio Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ASRT.

As of Wed Jan 28 2026, ASRT's PE ratio (Price to Earnings) is -39.4 and Price to Sales (PS) ratio is 8.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ASRT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Assertio Therapeutics Inc has provided -0.353 (multiply by 100 for percentage) rate of return.